Our laboratory is welcoming applications from ambitious junior researchers with at least 4 years of research experience (including PhD studies) to apply for the competitive research funding from the postdoctoral research training network The WINNINGNormandy Fellowship Programme | Région Normandie
Our laboratory is offering potential candidates a unique research environment, including long-standing expertise in functional in vivo and ex vivo cardiovascular evaluations and access to our wide panel of relevant experimental models of cardiovascular diseases ranging from myocardial infarction, ischemia-reperfusion injury, chronic heart failure, acute heart failure, metabolic syndrome-induced cardiomyopathy, chronic kidney-disease induced cardiomyopathy, and sepsis-induced cardiomyopathy. Please contact our lead PIs for more details:
Paulus Mulder (expertise in HF models) paul.mulder[at]univ-rouen.fr ORCID
Ebba Brakenhielm (expertise in cardiac lymphatics) ebba.brakenhielm[at]univ-rouen.fr ORCID
Jeremy Bellien (expertise in endothelial dysfunction) jeremy.bellien[at]univ-rouen.fr ORCID
Nous avons pour la rentrée 2021 quatres potentielles offres de financements de thèse dans le laboratoire:
- Rôle de molécules de co-signalisation immunitaire lymphatiques en immuno-onco-cardiologie : myocardites induites par les inhibiteurs des points de contrôle immunitaires.
- Impact délétère des particules d'usure des freins dans le syndrome métabolique.
- Un Traitement par un Antagoniste du récepteur minéralocorticoïde permet-t-il de limiter une aGgravation de l’Insuffisance Cardiaque à fraction d’éjection préservée suite à l’Ovariectomie de souris en Syndrome Métabolique ? (TRAGICO-SMet).
- Lactate de Sodium au cours du sepsis : (LactMet-Heart) impact métabolique sur la dysfonction cardio-vasculaire
A recent experimental study, directed by D Guerrout, published in Front Mol Biosci , describes the beneficial cardiac impact, on both diastolic and systolic functions, of blocking soluble epoxide hydrolase (sEH) during chronic kidney disease (CKD) induced by 5/6 nephrectomy (Nx) in mice. These beneficial effects may be mediated by the prevention of endothelial dysfunction, independent from kidney preservation and antihypertensor effect. Thus, inhibition of sEH holds a therapeutic potential in preventing type 4 cardiorenal syndrome.
Coraline Heron, a 1st year PhD student in the laboratory, has together with our collaborator, David Godefroy (Inserm U1239), used light sheet imaging to reveal the delicate network of cardiac lymphatics in mice. Their work was awarded with a 1st Prize at the yearly FASEB BioArts competition in 2020.
Some concerns about the prescription of drugs acting on the renin-angiotensin system (RAS) have emerged due to SARS COV2 and COVID-19 pandemic and the revelation of the fundamental role of ACE2 (angiotensin-converting enzyme 2) in COVID-19 infection. Indeed, SARS COV2 utilizes ACE2 as a membrane receptor to enter target cells. Consequently, the question arises whether RAS modulating drugs impact the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection. Here we discuss the evidence avilable on the impact of angiotensin-converting enzyme 1 inhibitors (ACEi) versus angiotensin II type 1 receptor blockers (ARB). Based on the currently available evidences, and as recommended by several medical societies, ACEi or ARB should not be systematically discontinued because to date no safety signal was raised with the use of these drugs.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Therapie. 2020;75(4):319-325.
doi: 10.1016/j.therap.2020.05.009.. PMID: 32553503
In a recent study from our laboratory, Pr Paul Mulder and colleagues have developed a new animal model of acute cardiac decompensation induced by salt overload. Using this model, they investigated whether heart rate reduction (HRR) opposes the acute decompensation‐related aggravation of cardiovascular dysfunction. Briefly, they found that acute HRR, induced by the If current inhibitor S38844, opposes cardiac decompensation by preventing aggravation of cardiovascular dysfunction, including reduced myocardial tissue perfusion and coronary relaxation. Importantly, the protective effects of HRR persist beyond the transient treatment, and led to partial prevention of the development of pulmonary congestion. Whether early transient HRR induced by If current inhibitors or other bradycardic agents, i.e. beta‐blockers, exerts beneficial effects in human ADHF warrants further investigation.
ESC Heart Failure https://doi.org/10.1002/ehf2.13094
Previous media articles on our research:
- Projet FHU CARNAVAL
- FASEB BIOART 2020
- RHU STOP-AS (@RHU_STOPAS) | FDNitter
- Projet RHU STOP-AS sélectioné
- Un reseau invisible au secours du coeur
- Prix Jean-Paul Binet
- Ma thèse en 180 secondes
- Prix "Don de soi -don de vie"
- Réseau ERA-CVD LYMIT-DIS
- Réseau FHU REMOD-VHF
- Helene Eltchaninoff, membre de la Fédération Hospitalo-Universitaire - Portail vidéo de l'Université de Rouen Normandie (univ-rouen.fr)